A pharmaceutical company has launched a new website providing details of its clinical trials.
Shire said the portal provides scientific, non-promotional summaries of studies in a consistent format for pharmacists and patients.
The group hopes the move will bolster its commitment to transparency in the reporting of trial results.
The company’s chief scientific officer, Eliseo Salinas, said: “The creation of this new website helps us achieve our goal to ensure that patients and their families, as well as physicians and other healthcare providers, have access to accurate information related to Shire medicines.
“It’s important for patients and their caregivers to understand all aspects associated with the treatment options they may be considering, and this new tool, which offers clinical trial data dating back to 2002, provides a central source to this information for Shire-sponsored trials of our medicines.”
The group specialises in attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases.
Shire Global Medical Affairs created the website, and its research and development compliance team is responsible for its content and maintenance.
Information is currently available on Adderall XR, Daytrana, Lialda, and ProAmatine
Copyright © PA Business 2007